Direct answer
Gilead Sciences competes against ViiV Healthcare, Merck, Bristol Myers Squibb, and AbbVie, but the overlap is not identical across every product or customer. The useful question is which profit pool is contested, which customer can switch, and what advantage is required to win.
ViiV Healthcare
ViiV Healthcare overlaps with Gilead Sciences in one or more products, customers or budget categories. The most useful comparison is not market capitalization; it is product scope, customer value proposition, unit economics and the amount of capital required to compete. For a rigorous comparison, evaluate ViiV Healthcare versus Gilead Sciences across customer overlap, product performance, pricing, distribution, switching costs, capital intensity and the ability to fund the next product or capacity cycle. A different business mix can make a simple margin or valuation comparison misleading.
Merck
Merck overlaps with Gilead Sciences in one or more products, customers or budget categories. The most useful comparison is not market capitalization; it is product scope, customer value proposition, unit economics and the amount of capital required to compete. For a rigorous comparison, evaluate Merck versus Gilead Sciences across customer overlap, product performance, pricing, distribution, switching costs, capital intensity and the ability to fund the next product or capacity cycle. A different business mix can make a simple margin or valuation comparison misleading.
Bristol Myers Squibb
Bristol Myers Squibb overlaps with Gilead Sciences in one or more products, customers or budget categories. The most useful comparison is not market capitalization; it is product scope, customer value proposition, unit economics and the amount of capital required to compete. For a rigorous comparison, evaluate Bristol Myers Squibb versus Gilead Sciences across customer overlap, product performance, pricing, distribution, switching costs, capital intensity and the ability to fund the next product or capacity cycle. A different business mix can make a simple margin or valuation comparison misleading.
AbbVie
AbbVie overlaps with Gilead Sciences in one or more products, customers or budget categories. The most useful comparison is not market capitalization; it is product scope, customer value proposition, unit economics and the amount of capital required to compete. For a rigorous comparison, evaluate AbbVie versus Gilead Sciences across customer overlap, product performance, pricing, distribution, switching costs, capital intensity and the ability to fund the next product or capacity cycle. A different business mix can make a simple margin or valuation comparison misleading.
Competitive dimensions that matter
| Dimension | Question for Gilead Sciences |
|---|---|
| Product | Does Gilead Sciences's offering solve the customer problem better or more completely? |
| Price | Is pricing supported by differentiated value or merely by a favorable cycle? |
| Distribution | Can competitors reach the same customers with similar efficiency? |
| Switching cost | What economic, technical or organizational friction makes a change difficult? |
| Scale | Does scale lower cost, improve data, expand selection or support larger R&D budgets? |
| Capital intensity | How much cash must be committed to defend the position? |
| Innovation | Is product leadership sustained through measurable adoption and outcomes? |
| Regulation | Does regulation protect incumbents, raise cost, or create disruption risk? |
How to tell whether the moat is strengthening
Do not label the company as having a "wide moat" without evidence. For Gilead Sciences, look for a combination of improving HIV revenue, oncology revenue, and R&D, resilient customer behavior and favorable movement in HIV franchise growth, and oncology uptake. If the company must continually cut price, overspend to retain customers or accept weaker returns, scale alone may not represent an advantage.
Competitive warning signs
Competitive erosion can appear before revenue declines. Watch for slower adoption, weaker renewal or repeat activity, price concessions, increased customer acquisition cost, rising R&D just to maintain parity, loss of strategic partners, or a competitor setting the pace of the product roadmap.
The relevant warning signs for Gilead Sciences should be mapped to franchise concentration, patent expirations, clinical failures, pricing pressure, and M&A execution.